Bimatoprost 0,03% efficacy and safety as a first-choice drug in patients with primary open-angle glaucoma

Purpose: To evaluate the efficacy and safety of Bimatoprost 0.03% (bimatan) treatment for patients with newly diagnosed open-angle glaucoma (POAG) I-II stages as the first line drug.

Methods: 64 eyes of 46 patients (26 men, 20 women) with newly diagnosed POAG I-II stages were included into the study. The average age of the men was 61.3 years, women - 65 years. The study comprised 31 patients (67.4% of 46 patients) with early glaucoma changes (mild, moderate) and 15 patients (32.6% of 46 patients) with advanced glaucoma changes. The patient's non-corrected visual acuity varied from 0.2 to 0.8. Prior to treatment all patients underwent a complex ophtalmological examination: visual acuity, perimetry, tomometry, tonography, gonioscopy and ophthalmoscopy. The examination in 14 days after treatment included of visual acuity, tonometry, tonography and in 3 months after treatment - visual acuity, perimetry, tomometry, tonography, gonioscopy and ophthalmoscopy.

All patients received instillation of Bimatoprost 0.03% (Bimatan) once daily in the evening at 8 p.m. Adverse reactions were reported at every step.

Results: After 14 days of Bimatoprost 0.03% instillations intraocular pressure (P0) level decreased from 17.2+3.1 to 13.9+1.8 mm Hg due to an increase in outflow facility (C) from 0.081+0.042 mm³/min/mm Hg to 0.198+0.044 mm³/min/mm Hg and the suppression of aqueous humor production (F) from 0.91+0.18 to 0.78+0.12 mm3/min (p<0,05). There were no significant changes in the hydrodynamic indicators after 3 months of treatment (p>0.05).

IOP reduced to the individual tolerance level due to bimatoprost 0.03% instillation in 100% of cases (64 eyes).

Conclusion: Bimatoprost 0.03% is an effective and safe drug for reducing IOP in patients with primary open-angle glaucoma I-II stages. The hypotensive effect is achieved by increasing the outflow of aqueous humor and the suppression of aqueous humor production. This agent is characterized by minor topical adverse reactions. Bimatoprost 0.03% may be recommended for POAG treatment to reduce IOP as the first line drug.

1. Alekseev V.N., Malevannaya O.A., Samikh El Khazh Nader. Causes of low adherence to treatment of patients with primary open-angle glaucoma. Oftalmologicheskie vedomosti. 2010; 4:37-39. (In Russ.).

2. Nesterov A.P. Pervichnaya glaukoma [Primary glaucoma]. Moscow: Meditsina Publ.; 1995: 242 p. (In Russ.).

3. Erichev V.P. Gipotenzivnaya terapiya pervichnoi otkrytougol’noi glau-komy fiksirovannymi kombinatsiyami lekarstvennykh sredstv: meto-dicheskie rekomendatsii [Antihypertensive therapy of primary open-angle glaucoma with fixed combinations of drugs: guidelines]. Moscow; 2012: 21 p. (In Russ.).

4. Astakhov Yu.S. New in the treatment of glaucoma. Field of view. 2012; 2(10):29-32. (In Russ.).

5. Egorov E.A. Glaukoma. Natsional’noe rukovodstvo [Glaucoma. National guide]. Moscow, GEOTAR-Media Publ.; 2013: 824.

6. Passo M.S., Palmer E.A., Van Buskirk E.M. Plasma timolol in glaucoma patients. Ophthalmology. 1984; 91:1361-1363. doi: 10.1016/s0161-6420(84)34141-0

7. Zagidulina A.Sh., Gumerova E.I., Kadyrov S.A., Basyrova A.R. Antihypertensive therarapy «At the start» for primary open-angle glaucoma. Bashkortostan Medical Journal. 2014; 9(2):52-55. (In Russ.).

8. Li T., Lindsley K., Rouse B.. Comparative effectiveness of first-line medications for primary open-angle glaucoma: a systematic review and network meta-analysis. Ophthalmology. 2016; 123:129-140. doi: 10.1002/14651858.cd011366

9. Brittain C.J., Saxena R., Waldock A. Prospective Switch Study from Timolol 0,5% and Latanoprost 0.005% to Bimatoprost 0.03%. Advances in Therapy. 2006; 23(1): 68-73. doi: 10.1007/bf02850348